Bringing World-Leading ctDNA Expertise to the Clinic
Broad Molecular Profiling For Targeted Cancer Care
Inivata’s proprietary technology is pioneering and draws on world-class research, based on original research conducted in the Rosenfeld lab at Cancer Research (CRUK), Cambridge and licensed from CRUK and University of Cambridge. The InVision® proprietary platform is a tagged-amplicon sequencing method, which allows amplification and deep sequencing of genomic regions spanning thousands of bases from individual copies of fragmented DNA.
Inivata’s proprietary technology is pioneering and draws on world-class research, based on original research conducted in the Rosenfeld lab at Cancer Research (CRUK), Cambridge and licensed from CRUK and University of Cambridge.
Plasma collection DNA extraction
ctDNA analysis
Bioinformatics analysis
Oncology report generated
Stand-out Sensitivity
InVision® has been developed to provide an exceptional level of sensitivity, while retaining a comprehensive coverage.
>99% of single nucleotide variants at an allele frequency of 0.25%-0.33% and >50% at an allele frequency of 0.06%-0.08%.
